Last reviewed · How we verify

NCT05938218: VRAP-DAAST

Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment

Status unknown NA Last updated 10 July 2023
What this trial tests

NA trial testing Intervention in Amyloidosis Cardiac in 60 participants. Status unknown.

Timeline
1 December 2023
Primary endpoint
1 December 2024
1 December 2025

Quick facts

Lead sponsorHeinrich-Heine University, Duesseldorf
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment60
Start date1 December 2023
Primary completion1 December 2024
Estimated completion1 December 2025
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Heinrich-Heine University, Duesseldorf

Who can join

Adults 18 to 100, any sex, with Amyloidosis Cardiac or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ATTR amyloidosis is a serious condition with significant morbidity and mortality. In Germany, there are numerous unreported cases of untreated patients, and diagnosing and initiating treatment often requires multiple specialized tests. To address this, a study is being conducted to determine if virtual reality (VR)-based patient education can improve diagnosis rates, treatment initiation, and medication adherence compared to standard education methods.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Amyloidosis Cardiac

Currently open trials in the same condition.

Other Heinrich-Heine University, Duesseldorf trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05938218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing